VEGFA and melanoma: Since the limitation of this preclinical study is that we used immunodeficient mice that lack lymphocytes, we also employed syngeneic mouse model using B16 melanoma cells and C57BL/6 mice to verify the role of other immune cells in the acquired resistance to anti-VEGF therapy (Supplementary Fig. 4).